Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
9 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Insmed (NASDAQ: INSM ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Insmed reported strong
HUTCHMED (China) (NASDAQ: HCM ) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. The full earnings call is available at Summary HUTCHMED (
Sanofi (NASDAQ: SNY ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Sanofi delivered a stro
On Monday, AstraZeneca (NASDAQ: AZN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary AstraZeneca reported a 6% growth in total revenue for the fi
Kyntra Bio reports $12 million in net income for Q2 2026, versus a $13.7 million net loss a year earlier, while FG3246, FG3180 and roxadustat programs advance.
LiveWire Group Inc. (NYSE: LVWR ) stock surged more than 71% on Monday after the electric motorcycle maker reported strong second-quarter revenue growth and narrower losses. Second-Quarter Results Boost Investor Sentiment On Thursday, LiveWire reported second-quarter results for the period ended June 30. Revenue increa
AstraZeneca Q2 2026 earnings beat on cancer drug sales
Rev. $15.38B (est $15.42B) Core EPS $2.63 (est $2.48) Reconfirms Rev, Core EPS Guidance For FY On Track To Deliver Ambition Of $80B In Rev In 2030
AstraZeneca PLC Q2 2026 Earnings Preview